NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Veru Inc. (VERU) Stock Analysis

Veru Inc. (VERU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VERU

$2.30

−$0.08 (−3.36%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VERU with… →

VERU Key Statistics

As of Oct 21, 2026
Trading
Open
$2.37
Previous Close
$2.38
Day's Range
2.28–2.41
52-Week Range
2.05–7.33
Volume
99.81K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.20
Valuation
Market Cap
$39.22M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
3.60
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.61
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$22.73M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
17.05M
1-Year Return
−46.51%
Dividend and dates
Avg Volume
236.99K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VERU closed at $2.30, −46.51% over 1 year.

Veru Inc. (VERU) has a market capitalization of $39.22M.

In fiscal 2025, VERU reported revenue of $0.00.

VERU Stock Return by Calendar Year

Veru Inc. (VERU) 10-year return: what $10,000 became

1 year
$10,000 $5,349
−46.51%
5 years
$10,000 $276
−97.24%
10 years
$10,000 $2,110
−78.90%

If you had invested $10,000 in Veru Inc. (VERU) 10 years ago, at the close on October 21, 2016, it would have been worth $2,110 at the close on October 21, 2026: −78.90% in total, −14.41% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.48%
2025−67.08%
2024−9.72%
2023−86.36%
2022−10.36%
2021−31.91%
2020+158.21%
2019+139.29%
2018+22.81%
2017+25.27%
2016 (partial year)−35.92%

As of October 21, 2026.

VERU Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$22.73M—
2024$0.00−$37.80M—
2023$16.30M−$93.15M−571.6%
2022$39.35M−$84.04M−213.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$35.53M−$22.73M—
2024$0.00$5.85M−$37.39M−$37.80M—
2023$16.30M$7.57M−$95.61M−$93.15M−571.6%
2022$39.35M$30.59M−$83.49M−$84.04M−213.5%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Veru Inc. (VERU) carries a market capitalisation of $39.22M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 20 employees.

The most recent close on file for VERU is $2.30, dated October 21, 2026. That is −$0.08 (−3.36%) against the previous close. The 52-week range on file runs from $2.05 to $7.33. The latest close sits 12.2% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $22.73M. Trailing earnings per share are −0.61.

Across the 4 fiscal years on file, revenue moves from $39.35M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 3.6.

Over the trailing twelve months the total return is −46.51%. Across 10 years the annualized return works out at −14.41%. The reported beta is −1.2. Daily returns over the trailing 10 years annualize to a volatility of 113.25%.

Growth & Income

The record shows no dividend for VERU.

2026 is still running; the total return is +7.48% year to date. The strongest complete calendar year on file is 2020 at +158.21%; the weakest is 2023 at −86.36%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Veru Inc. (VERU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Veru Inc. VERU $39.22M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Veru Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Veru Inc.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Visit website →